This discussion highlights the importance of recognizing that everyone can engage in leading within their roles, while also ...

How hospitals are facilitating knowledge sharing and accelerating the implementation of value-based health care with Value ...

The final months of 2024 brought several developments that will have far-reaching implications for global health delivery efforts in the years to come. Closest to home for those of us in the ...

The best multimodal approach for resectable esophageal adenocarcinoma is unclear. New research findings are summarized in a short video.

Factor VIII gene was introduced into hematopoietic stem cells in men with hemophilia. The annualized bleeding rate went from 10 to 0. No worrisome gene integrations were seen. The content of this ...

Carmel Shachar is an assistant clinical professor of law and faculty director of the Health Law and Policy Clinic at Harvard Law School. Stephen Morrissey, the interviewer, is the Executive ...

Key aspects of the Cedars-Sinai Community Connect Program, and its pilot program of targeted grantmaking, are the need to establish a resource and referral platform; to provide dedicated resources ...

Since April 2022, more than 220,000 immigrants seeking asylum or other legal status have arrived in New York City from southern U.S. border states. The New York City Department of Homeless Services ...

A quantitative alcohol history should be recorded for all patients, because alcohol use contributes to many physical and mental disorders. A person-centered, nonjudgmental approach should be adopted.

An urgent health care workforce crisis is looming. In the United States, a country plagued by disparate health outcomes across its geographic regions, relative physician “deserts” (i.e ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.